This article is more than 5 years old. Information may no longer be current.

OPKO Health names renal division senior VP for clinical R&D

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

OPKO Health Inc. has named Akhtar Ashfaq, MD, FACP, FASN senior vice president, clinical research and development of the renal division.

In this role, Ashfaq will support the ongoing adoption of Rayaldee (calcifediol) extended-release capsules by health care professionals who care for patients with stage 3 or 4 chronic kidney disease.

He will lead the further development of Rayaldee to treat secondary hyperparathyroidism (SHPT) in adults on hemodialysis with vitamin D insufficiency.  He also will lead the development of Alpharen (fermagate) tablets for the treatment of hyperphosphatemia in adults with stage 5 CKD.

Ashfaq was previously with AstraZeneca, where he served as executive director and head of the CKD Program within Global Medical Affairs.  Prior to Astra Zeneca, Ashfaq was with Amgen where he served as Medical Director and North American Medical Lead for Epogen and Aranesp.  He is an academic nephrologist by training and has more than 15 years of clinical experience.